@JudithTrotman1 @MorieGertz @AjHematology Very reasonable approach. I don’t usually use BTKi in frontline. A study suggested BR had better PFS when compared to DRC, both offer time limited therapy which is a plus. Also another abstract suggesting better ou
Trend (only) to superior PFS with BR. I wonder if a matched pair analysis could have been possible? Likely too small a population. Reassuring comparable responses with 4BR as with 6 gives comfort if obliged to stop. #wmsm
RT @chanyooncheah: Nice retrospective data from @MayoMyeloma @MayoLymphoma addressing comparative efficacy or BR vs DRC in Waldenstrom’s ma…
Nice retrospective data from @MayoMyeloma @MayoLymphoma addressing comparative efficacy or BR vs DRC in Waldenstrom’s macrogloblinemia #lymSM #mmSM https://t.co/7K1QS9IN4K
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia https://t.co/wfiiloReu6
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia https://t.co/ijPMsd0KR5